Ligand Pharmaceuticals | LGND - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
Agenus USD -199.08M 22.15M 2026-06
Amgen USD 11.69B 2.5B 2026-06
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 465.53M 148.45M 2026-06
Baxter International USD 6.21B 163M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Eli Lilly USD 33.88B 2.68B 2026-06
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Enviri Corporation USD 233.18M 21.88M 2026-03
Gilead Sciences USD 11.74B 11.77B 2026-06
GlaxoSmithKline GBP 17.64B 223M 2026-06
Glaxosmithkline GBP 17.42B 4.64B 2026-03
Heron Therapeutics USD 6.91M 2.23M 2026-06
Insmed USD 757.49M 52.64M 2026-06
Intrexon USD 43.17M 75.33M 2024-06
Ionis Pharmaceuticals USD 439.74M 51.68M 2026-06
Karyopharm Therapeutics USD -265.65M 27.28M 2026-03
Ligand Pharmaceuticals USD 967.52M 29.81M 2026-06
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 41.93B 3.94B 2026-06
Pacira USD 671.98M 18.08M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Veracyte USD 1.39B 44M 2026-06